سعر اتكوكسيب 90 مجم 30 قرص 2025

Etoricoxib 90 mg tablets, 30 tablets (3 strips); selective COX-2 inhibitor NSAID (Atco Pharma, Egypt).

• Symptomatic relief of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.Population: Adults and adolescents 16 years and olderelectronic medicines compendium (eMC)
• Pain and signs of inflammation associated with acute gouty arthritis.Population: Adults and adolescents 16 years and olderelectronic medicines compendium (eMC)
• Short-term treatment of moderate pain associated with dental surgery.Population: Adults and adolescents 16 years and olderelectronic medicines compendium (eMC)

• Very common: abdominal pain. Common: alveolar osteitis, oedema/fluid retention, dizziness, headache, palpitations, arrhythmia, hypertension, bronchospasm, constipation, flatulence, gastritis, heartburn, diarrhoea, dyspepsia, nausea, vomiting, oesophagitis, oral ulcer, ALT/AST increase, ecchymosis, asthenia/fatigue, flu-like disease.International label, same formulation · electronic medicines compendium (eMC)
• Uncommon or rare: congestive heart failure, myocardial infarction, stroke, gastroduodenal ulcer/bleeding, renal insufficiency, hyperkalaemia, anaphylaxis/angioedema, hepatitis, hepatic failure, Stevens-Johnson syndrome, toxic epidermal necrolysis.International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity to etoricoxib or excipients; bronchospasm, acute rhinitis, nasal polyps, angioedema, urticaria or allergic-type reactions after aspirin or NSAIDs (including COX-2 inhibitors).International label, same formulation · electronic medicines compendium (eMC)
• Active peptic ulceration or active gastrointestinal bleeding; inflammatory bowel disease.International label, same formulation · electronic medicines compendium (eMC)
• Congestive heart failure (NYHA II-IV); hypertension persistently above 140/90 mmHg and not adequately controlled; established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.International label, same formulation · electronic medicines compendium (eMC)

• Upper gastrointestinal perforation, ulcers or bleeding (sometimes fatal); risk higher in the elderly, with other NSAIDs or aspirin (even low dose) and with prior GI disease.International label, same formulation · electronic medicines compendium (eMC)
• Cardiovascular thrombotic risk (myocardial infarction, stroke) may increase with dose and duration; treat patients with significant cardiovascular risk factors only after careful consideration; not a substitute for aspirin for cardiovascular prophylaxis.International label, same formulation · electronic medicines compendium (eMC)
• Fluid retention, oedema and hypertension (possibly more frequent and severe than with some other NSAIDs, particularly at high doses); control blood pressure before treatment and monitor it within 2 weeks and periodically.International label, same formulation · electronic medicines compendium (eMC)

• Warfarin and other oral anticoagulantsEtoricoxib 120 mg raised INR by about 13%; monitor INR closely when starting or changing the dose.electronic medicines compendium (eMC)
• Diuretics, ACE inhibitors and angiotensin II antagonistsReduced antihypertensive effect and possible deterioration of renal function (acute renal failure) in compromised patients; ensure hydration and monitor renal function.electronic medicines compendium (eMC)
• Acetylsalicylic acidLow-dose aspirin may be used but increases the rate of GI ulceration; higher aspirin doses or other NSAIDs are not recommended.electronic medicines compendium (eMC)

• Contraindicated in pregnancy (no human data; reproductive toxicity in animals); may cause uterine inertia and premature closure of the ductus arteriosus in the last trimester; discontinue if pregnancy occurs. Not recommended in women attempting to conceive.International label, same formulation · electronic medicines compendium (eMC)
• Contraindicated: women using etoricoxib must not breast-feed (excreted in rat milk).International label, same formulation · electronic medicines compendium (eMC)

• Etoricoxib: Selective COX-2 inhibitor within the clinical dose range; no inhibition of COX-1 at doses up to 150 mg daily and no effect on platelet function.